Next Article in Journal
STAT5 is Expressed in CD34+/CD38 Stem Cells and Serves as a Potential Molecular Target in Ph-Negative Myeloproliferative Neoplasms
Next Article in Special Issue
Multi-Gene Prognostic Signatures and Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in ER-Positive, HER2-Negative Breast Cancer Patients
Previous Article in Journal
Knockdown of UTX/KDM6A Enriches Precursor Cell Populations in Urothelial Cell Cultures and Cell Lines
Previous Article in Special Issue
Personalized Medicine: Recent Progress in Cancer Therapy
Open AccessReview

Current Strategies and Future Perspectives for Precision Medicine in Pancreatic Cancer

Department of Medicine II, University Hospital, LMU Munich, 81377 Munich, Germany
*
Author to whom correspondence should be addressed.
Cancers 2020, 12(4), 1024; https://doi.org/10.3390/cancers12041024
Received: 30 March 2020 / Revised: 17 April 2020 / Accepted: 18 April 2020 / Published: 21 April 2020
(This article belongs to the Special Issue Personalized Medicine: Recent Progress in Cancer Therapy)
Current standard-of-care for patients with pancreatic ductal adenocarcinoma (PDAC) focusses on chemotherapeutic regimens and pancreatic cancer surgery. However, limited treatment options, late diagnosis in advanced tumor stages and the aggressive behavior of PDAC contribute to the high mortality of the disease. Consequently, there is an urgent need of precision medicine for pancreatic cancer patients. All over the world, numerous initiatives started in recent years to translate novel scientific discoveries into prospective clinical trials. One major approach pursues the stratification of PDAC patients according the tumor transcriptome to predict treatment response. Other strategies concentrate on genomic alterations and the identification of individualized targeted therapies. Further experimental studies are ongoing to detect novel biomarkers for cancer diagnosis, subtyping, treatment response prediction or clinical outcome. However, the challenge remains to transfer the knowledge into clinical practice. In this review, we summarize current literature and knowledge and highlight novel concepts of basic and clinical research uncovering suitable biomarkers and targeted therapies. Thus, we provide an overview of preclinical and clinical efforts of precision medicine in pancreatic cancer. View Full-Text
Keywords: pancreatic ductal adenocarcinoma; cancer subtypes; targeted therapy; biomarker; epigenetic; metabolome; PDAC initiatives pancreatic ductal adenocarcinoma; cancer subtypes; targeted therapy; biomarker; epigenetic; metabolome; PDAC initiatives
Show Figures

Figure 1

MDPI and ACS Style

Regel, I.; Mayerle, J.; Ujjwal Mukund, M. Current Strategies and Future Perspectives for Precision Medicine in Pancreatic Cancer. Cancers 2020, 12, 1024.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop